Dr. Jonathan R. Strosberg on the NETTER-1 Trial and its Impact on Patients With Midgut NETs
February 17th 2016The trial looked at radionuclide therapy Lu-Dotatate in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.
Watch
Dr. Peter Beitsch on the Benefits of Grouping Patients With Breast Cancer by Subtype for Trials
February 16th 2016Beitsch says that while having a study that incorporates several thousands of patients will potentially produce statistically significant results, these larger groups may not account for subtypes in each patient's individual cancer.
Watch
Dr. Sylvia Asa on Treating Different Types of Thyroid Cancer
February 16th 2016Asa says one of the most common mutations in subtypes of thyroid cancer is the BRAF mutation. She adds that while the mutation is common, a good number of patients do not respond to BRAF-targeted therapies, hinting that these subtypes are more complex than previously thought.
Watch
Dr. Matthew Cooperberg on the Effectiveness of Active Surveillance in Prostate Cancer
February 13th 2016Cooperberg says the likelihood of a patient for staying on active surveillance for 10 or 15 years is around 50%, though men who stay on active surveillance for between 6 months and 5 years generally see progression in their disease.
Watch
Dr. Jennifer Wu on Proliferations and Mutations in Colorectal Cancer
February 12th 2016Jennifer Wu, MD, discusses the issue of deficiencies in enzymes that fix mismatch repairs in colorectal cancer. Wu says targeting the cancer-specific enzymes which allow tumors to repair themselves could stop tumor growth in patients.
Watch
Dr. David Reardon on Immunotherapy and Rindopepimut in the Glioblastoma Treatment Paradigm
February 10th 2016David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the future of immunotherapy in glioblastoma and how rindopepimut fits into that paradigm.
Watch
Dr. Mark Gilbert on Genetics as a Predictive Tool for Treatment Response in Brain Cancer
February 10th 2016Mark Gilbert, MD, neuro-oncologist, chief of neuro-oncology, National Institute of Health, discusses predicting how a patient's brain tumor might act and respond to treatment based on their genetics.
Watch
Dr. Nicholas A. Butowski on Convection-Enhanced Delivery of Nanoliposomal Irinotecan in Brain Cancer
February 9th 2016Nicholas A. Butowski, MD, director, Translational Research in Neuro-Oncology, University of California, San Francisco, discusses the eligibility of patients with glioblastoma to receive a convection-enhanced delivery of nanoliposomal irinotecan with real-time imaging.
Watch
Dr. Rimas Lukas on Searching for Biomarkers in Glioblastoma
February 9th 2016​Rimas Lukas, MD, director, Medical Neuro-Oncology, co-director, Neurology Medical Student Clerkship Program, The University of Chicago Medical Center, discusses the next steps following a phase I study looking at atezolizumab in glioblastoma.
Watch
Dr. Jonathan R. Strosberg on 177-Lu-Dotatate in Patients With Neuroendocrine Tumors
February 6th 2016Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the targeted, systemic radiation treatment 177-Lu-Dotatate (Lutathera), a somatostatin analogue peptide, in patients with neuroendocrine tumors.
Watch
Dr. Oliver Sartor on Doubling the Dosage of Radium-223 in Patients With CRPC
February 6th 2016Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses how radium-223 dichloride became deemed safe in patients with bone-metastatic castration-resistant prostate cancer (CRPC). The treatment was tested in an open-label phase I/II trial where patients were given 6 additional doses of radium-223 on top of their original 6-dose regimen.
Watch
Dr. Carey Anders on Exclusion of Patients With Brain Metastases From Clinical Trials
February 6th 2016Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, UNC Chapel Hill, discusses the exclusion of patients with breast cancer who have developed brain metastases from clinical trials.
Watch
Dr. Amitabh Chak on New Screening Methods for Esophageal Cancer
February 5th 2016Amitabh Chak, MD, MS, professor of Medicine, director, Clinical Research, Division of Gastroenterolgy Diseases, Case Western Reserve University, discusses advances in esophageal cancer. Chak says some of the more "exciting" developments in the treatment of the disease are transnasal endoscopy, as well as a new type of screening device that acts as a "pap smear" for the esophagus.
Watch